K N Roy Chengappa

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Recovery and functional outcomes following olanzapine treatment for bipolar I mania
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213 2593, USA
    Bipolar Disord 7:68-76. 2005
  2. ncbi request reprint A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type
    Kn Roy Chengappa
    Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, and Mayview State Hospital, Pittsburgh, PA, USA
    Bipolar Disord 9:609-17. 2007
  3. doi request reprint Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder
    K N Roy Chengappa
    Comprehensive Recovery Services, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O Hara St, Pittsburgh, PA
    J Clin Psychiatry 74:1076-83. 2013
  4. doi request reprint A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213 2593, USA
    Schizophr Res 142:145-52. 2012
  5. ncbi request reprint Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial
    K N Roy Chengappa
    Department of Psychiatry, University of Pittsburgh Medical Center and Mayview State Hospital, Pittsburgh, PA, USA
    J Clin Psychiatry 67:1698-706. 2006
  6. ncbi request reprint Dosage and administration issues of antipsychotic agents (and adjunctive medicines) in the acute stabilization of psychoses
    K N Roy Chengappa
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
    CNS Spectr 9:6-10. 2004
  7. ncbi request reprint The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype
    Ranita Basu
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    Bipolar Disord 6:314-8. 2004
  8. ncbi request reprint Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, Mayview State Hospital, University of Pittsburgh Medical Center, PA 15213 2593, USA
    Bipolar Disord 5:1-5. 2003
  9. doi request reprint The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population
    Jaspreet S Brar
    School of Medicine, Western Psychiatric Institute and Clinic and University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Ann Clin Psychiatry 20:139-44. 2008
  10. ncbi request reprint Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 2593, USA
    Clin Ther 24:1576-84. 2002

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Recovery and functional outcomes following olanzapine treatment for bipolar I mania
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213 2593, USA
    Bipolar Disord 7:68-76. 2005
    ..Typical experimental categorizations of treatment responses in bipolar disorder (BPD) patients may have limited relationship to clinical recovery or functional status, and there is inadequate research on such clinically important outcomes...
  2. ncbi request reprint A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type
    Kn Roy Chengappa
    Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, and Mayview State Hospital, Pittsburgh, PA, USA
    Bipolar Disord 9:609-17. 2007
    ..This pilot study evaluated the efficacy and safety of adjunctive topiramate compared with placebo in the treatment of patients with a diagnosis of schizoaffective disorder, bipolar type (SAD-BT)...
  3. doi request reprint Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder
    K N Roy Chengappa
    Comprehensive Recovery Services, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O Hara St, Pittsburgh, PA
    J Clin Psychiatry 74:1076-83. 2013
    ..We assessed the cognitive effects of a standardized extract of the medicinal herb Withania somnifera (WSE) in bipolar disorder...
  4. doi request reprint A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213 2593, USA
    Schizophr Res 142:145-52. 2012
    ....
  5. ncbi request reprint Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial
    K N Roy Chengappa
    Department of Psychiatry, University of Pittsburgh Medical Center and Mayview State Hospital, Pittsburgh, PA, USA
    J Clin Psychiatry 67:1698-706. 2006
    ..To investigate the efficacy and safety of topiramate versus placebo as adjunctive therapy for the outpatient management of bipolar I disorder...
  6. ncbi request reprint Dosage and administration issues of antipsychotic agents (and adjunctive medicines) in the acute stabilization of psychoses
    K N Roy Chengappa
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
    CNS Spectr 9:6-10. 2004
    ..The speed of titration to an effective target dose for these newer agents are addressed as well...
  7. ncbi request reprint The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype
    Ranita Basu
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    Bipolar Disord 6:314-8. 2004
    ..To evaluate the point prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar type...
  8. ncbi request reprint Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, Mayview State Hospital, University of Pittsburgh Medical Center, PA 15213 2593, USA
    Bipolar Disord 5:1-5. 2003
    ....
  9. doi request reprint The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population
    Jaspreet S Brar
    School of Medicine, Western Psychiatric Institute and Clinic and University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Ann Clin Psychiatry 20:139-44. 2008
    ..However, the data with regard to the effect of switching from first- to second-generation antipsychotic agents on pre-existing dyskinetic symptoms during routine clinical care is sparse...
  10. ncbi request reprint Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 2593, USA
    Clin Ther 24:1576-84. 2002
    ..Among the newer anticonvulsant agents, topiramate is a candidate agent for bipolar disorder and is associated with weight loss when used as adjunctive treatment...
  11. ncbi request reprint A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 2593, USA
    Clin Ther 25:530-41. 2003
    ..Available data for other second-generation antipsychotic agents show that quetiapine may have better efficacy in improving agitation compared with haloperidol...
  12. doi request reprint Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic
    Abdulkader Alam
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2593, USA
    Gen Hosp Psychiatry 34:660-4. 2012
    ..OSA has received more attention recently, but the literature on OSA is scant in patients with severe mental illness (SMI). This project was undertaken to improve clinician knowledge and screening of OSA in persons with SMI...
  13. ncbi request reprint Leukopenia in clozapine treated patients may be induced by other drugs: a case series
    Mary Jo Imbarlina
    Special Studies Center at Mayview State Hospital, Pittsburgh, PA 15213, USA
    Eur Psychiatry 19:506-9. 2004
    ..When adding potentially leukopenic drugs, clinicians should look for possible alternatives especially as clozapine is often a drug used as the last resort in treatment refractory schizophrenia...
  14. doi request reprint Lithium specificity in bipolar illness: a classic agent for the classic disorder
    Samuel Gershon
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Bipolar Disord 11:34-44. 2009
    ..We demonstrate that lithium possesses significant clinical and therapeutic efficacy that is very individual and thus remains the treatment of choice for bipolar disorder when used specifically in select patients...
  15. doi request reprint Identifying and treating cognitive impairment in bipolar disorder
    Joseph F Goldberg
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Bipolar Disord 11:123-37. 2009
    ....
  16. ncbi request reprint Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate
    Ranita Basu
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA Veterans Administration Health System, Highland Drive, Pittsburgh, PA, USA
    Asian J Psychiatr 2:106-11. 2009
    ..Furthermore, lower thresholds for waist circumference have also been recommended for Asians...
  17. ncbi request reprint Weight gain and metabolic issues of medicines used for bipolar disorder
    Andrea Fagiolini
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    Curr Psychiatry Rep 9:521-8. 2007
    ....
  18. ncbi request reprint Treatment of bipolar mania with atypical antipsychotics
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Expert Rev Neurother 4:S17-25. 2004
    ..The ultimate choice of the atypical agent will depend on the patient's individual needs, but atypical antipsychotics are clinically effective options for achieving mood stabilization in the treatment of acute bipolar mania...
  19. ncbi request reprint The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital
    Haranath Parepally
    Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:437-40. 2002
    ..e. use of blood and organ system monitoring with mood stabilizers). At the end of treatment, olanzapine-treated subjects had statistically significantly lesser concomitant medicine usage compared to control subjects...
  20. ncbi request reprint Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden
    Andrea Fagiolini
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA
    CNS Drugs 22:655-69. 2008
    ..Prevention of weight gain and metabolic disturbances or early intervention when these are present in bipolar disorder could result in significant health and economic benefits...
  21. ncbi request reprint Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry
    K N Roy Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Am J Psychiatry 160:1636-42. 2003
    ..Utilizing data from a previously characterized registry of subjects with bipolar illness, the authors examined age at onset of the first illness episode in cohorts of subjects born from 1900 through 1939 and from 1940 through 1959...
  22. ncbi request reprint The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder
    Ravi Kant
    Head Injury Clinic, Pittsburgh, Pennsylvania, USA
    J Child Adolesc Psychopharmacol 14:57-63. 2004
    ..This report describes the use of clozapine in adolescents with diagnoses of bipolar disorder, intermittent explosive disorder (IED), and posttraumatic stress disorder (PTSD)...
  23. doi request reprint Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report
    S Nassir Ghaemi
    Bipolar Disorder Research Program, Department of Psychiatry, Emory University, Atlanta, GA 30322, USA
    Bipolar Disord 10:117-28. 2008
    ....
  24. ncbi request reprint The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders
    David C Mamo
    Centre for Addiction and Mental Health, Toronto, Canada
    Int J Geriatr Psychiatry 17:1012-7. 2002
    ..It has been suggested, therefore, that older patients with schizophrenia could be maintained on reduced doses of conventional neuroleptics...
  25. ncbi request reprint A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study
    K N Roy Chengappa
    Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017 1599, USA
    Can J Psychiatry 48:187-94. 2003
    ..To evaluate the efficacy and safety of administering quetiapine once vs twice daily...
  26. ncbi request reprint Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  27. doi request reprint Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change
    Anabel Martinez-Aran
    Bipolar Disorders Program, IDIBAPS, CIBER SAM, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Bipolar Disord 10:566-79. 2008
    ..Using efficacy studies as illustrations, the authors review and recommend changes in the reporting of traditional clinical outcomes both in the acute and maintenance phases of bipolar disorder...
  28. pmc Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type
    Andrea H Weinberger
    J Clin Psychopharmacol 28:247-8. 2008
  29. ncbi request reprint Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
    ....